No Carolina / NY / Florida
Ph: 561.316.3330

Singaporean Telehealth Platform ORA Raises $10 Million USD Series A to Modernise Healthcare in the Region

The funding will be used to double down on the centralised software platform, geographical expansion and development of a new consumer healthcare offering

Summation

  • We achieved post marketing breakeven at the end of last year on a group level after just 20 months of going live and have a very clear and believable path to profitability that is imminently ahead of us.
  • We are inspired and supportive of their mission to become the “ Healthcare House of Brands” for the ~1B people in South East Asia and GCC who are underserved by the traditional healthcare system.
  • Their combined focus on specialised, and often taboo, healthcare verticals as well as a direct-to-patient approach has led the team to clearly differentiate itself while delivering market-leading unit economics that meet the tailored needs of patients across the full value chain.

Singaporean telehealth platform ORA has raised a $10 million USD Series A funding. This is the largest telehealth Series A in South-East Asia and was co-led by TNB Aura and Antler with participation from Gobi Partners, Kairous Capital and GMA Ventures, bringing total funding to date above $17 million USD.

ORA is the fastest-growing and biggest vertically-integrated telehealth platform in South East Asia delivering over 250,000 consultations and has experienced uninterrupted monthly growth since its 2021 launch.

ORA has launched three brands that serve the modern patient living with chronic conditions, making treatment more accessible, convenient and personal. Modules is a first to market online dermatology experience making personalised, prescription skincare accessible with 676 different formulations, andSons offers male health solutions and OVA delivers female reproductive healthcare.

Founded by former ZALORA CMO Elias Pour, ORA is uniquely positioned with a diverse, proven leadership team with rich backgrounds across health, tech and consumer brands. Backed by a robust medical advisory board, ORA’s R&D team draws on experience from L’Oréal and Sephora creating high-touch products and experiences that are IP’d and 100% in-house developed.

With a strong attention to customer experience, first to market solutions like Modules, andSons and Ova are meeting modern customer expectations head on. These interactions are translating into deeper patient relationships, building retention rates only rivalled by subscription models like Netflix and unrivalled within the industry.

90% of ORA’s patients are first to condition, under 38 years old and have never been treated before. The disconnect between this younger patient population and the traditional healthcare model is ORA’s biggest opportunity. These new patients have a different set of demands such as flexibility and speed which ORA’s telemedicine model is perfectly placed to treat. ORA’s seamless end-to-end experience joins up the fragmented traditional model, linking consultation, education, pharmacy, delivery and post purchase care for unparalleled convenience.

“ORA is on a mission to deliver high touch, high-quality care to millions of patients and with our continued growth story throughout SEA, we are thrilled with today’s announcement.” said Elias Pour, ORA’s founder and CEO. “ORA has had over 6 million patient touch points provide us with valuable health data through extensive health evaluations and consultation online. This has brought unique insights into these patient’s healthcare expectations that has and will inform future innovations with our key partners.”

“We have the high growth potential of DTC, with a very high percentage of healthcare expenditure in our region being out of pocket. This is powered by an underlying SAAS type of recurring revenue, with subscriptions counting for more than 70% of our revenue and our retention is better than Netflix with 10x the monthly order value. We achieved post marketing breakeven at the end of last year on a group level after just 20 months of going live and have a very clear and believable path to profitability that is imminently ahead of us.

With this new round of funding ORA will seek to expand its presence into new territories, both geographically and with new offerings. Later this year ORA’s brands will arrive in retail across 1300 tier one stores bringing its accessible, medically-backed range of products to shelves. Looking at different geographies there are opportunities to expand into regions like the GCC.

Charles Wong, Founding Partner at TNB Aura commented: “Since ORA’s early days, TNB Aura has been a firm believer and strong supporter of Elias and the ORA team in their unwavering mission to provide access to affordable high-quality healthcare. Their combined focus on specialised, and often taboo, healthcare verticals as well as a direct-to-patient approach has led the team to clearly differentiate itself while delivering market-leading unit economics that meet the tailored needs of patients across the full value chain.”

Teddy Himler – Global Partner at Antler added: “Elias and team have learned from the extraordinary rise of telehealth globally and have applied it masterfully to the idiosyncratic (and often challenging) South East Asia region. We are inspired and supportive of their mission to become the “ Healthcare House of Brands” for the ~1B people in South East Asia and GCC who are underserved by the traditional healthcare system. We think ORA’s platform approach is the future of direct-to-patient healthcare globally.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

- Advertisement -

spot_img

- Advertisement -

Enifer Secures €36M In Funding

Enifer, a biotech scaleup is gearing up the production of its PEKILO® mycoprotein with a new €33M factory located in Kirkkonummi, Finland. With already existing collaborations with the world’s leading food and feed companies, Enifer is prepared to annually upcycle food industry side streams into up to 3,000 tons of its sustainable fungi-based protein

Phenomix Sciences Raises $7.8M in Funding to Accelerate Adoption of Obesity Precision Medicine

Funding will accelerate the commercialization and adoption of the MyPhenome™ test in the obesity specialist market and the wider industry. The MyPhenome test equips physicians with essential tools to develop effective treatment plans including lifestyle and diet intervention as well as medication and/or procedure recommendations reports Phenomix Sciences.

R3 Vascular Announces $87 Million in Series B Financing

R3 Vascular will use the proceeds to support the ELITE FDA IDE pivotal trial of its best-in-class bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD. 

By using this website you agree to accept Medical Device News Magazine Privacy Policy